ESR1 and breast cancer: Furthermore, low ER expression patients received limited benefit from adjuvant hormonal therapy, indicating that the ER positivity cutoff should be redefined as 10%, to better predict the treatment response and disease outcome.19 In addition, these results may support the use of ablative therapy in breast cancer, which has often been challenged due to the lack of pathological examination of the final surgical specimen.